English English | 中文 中文


Recent Liver Research Articles

Recently published articles from Liver Research.

Vitamins and non-alcoholic fatty liver disease: A molecular insight☆

Available online 4 April 2021
Sana Raza | Archana Tewari | Sangam Rajak | Rohit A. Sinha

The incidence of non-alcoholic fatty liver disease (NAFLD) is rising rapidly across the globe. NAFLD pathogenesis is largely driven by an imbalance in hepatic energy metabolism and at present, there...

Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: A nationwide hospitalization analysis

March 2021
Simcha Weissman | Saad Saleem | Sachit Sharma | Menashe Krupka | Faisal Inayat | Muhammad Aziz | James H. Tabibian

Anti-neoplastic immunotherapy has revolutionized cancer management; however, its safety profile with respect to liver-related injury remains largely unexplored. Herein, we analyzed a United States national...

A fluorescence imaging based-assay to monitor mitophagy in cultured hepatocytes and mouse liver

March 2021
Xiaowen Ma | Wen-Xing Ding

Mitophagy is a lysosomal degradation pathway that selectively removes damaged, aged and dysfunctional mitochondria. Recent advances in understanding mitophagy highlight its importance in various physiological...

B cell dysfunction in chronic hepatitis B virus infection

March 2021
Lijie Ma | Xuehua Sun | Xiaoni Kong | Yueqiu Gao

Chronic hepatitis B (CHB) remains a global health problem. The persistence of hepatitis B surface antigen (HBsAg) in the blood for longer than 6 months after the initial infection is a sign of CHB....

Severe bile duct complication after yttrium-90 radioembolization therapy in a patient with recurrent hepatocellular carcinoma after liver transplantation: A case report

March 2021
Jian-Wen Zhang | Zhen-Yu Yu | Hai-Bo Li | Shu-Hong Yi | Wei Liu | Yang Yang | Guo-Ying Wang

Patients with recurrent hepatocellular carcinoma (HCC) following liver transplantation (LT) have a poor prognosis owing to rapid tumor progression. Yttrium-90 radioembolization (90Y-RE) has been shown...

Expert consensus on split-liver transplantation

March 2021

With the dawn of organ donation after a citizen's death in China, the use of split-liver transplantation (SLT) can effectively increase the source of donor liver, reduce the waiting time for organ transplantation...

Impact of liver enzymes on SARS-CoV-2 infection and the severity of clinical course of COVID-19

March 2021
Fátima Higuera-de la Tijera | Alfredo Servín-Caamaño | Daniel Reyes-Herrera | Argelia Flores-López | Enrique J.A. Robiou-Vivero | Felipe Martínez-Rivera | Victor Galindo-Hernández | Oscar Chapa-Azuela | Alfonso Chávez-Morales | Victor H. Rosales-Salyano

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the current pandemic, can have multi-organ impact. Recent studies show that liver injury could be a manifestation...

Mesenchymal stem cells therapy for acute liver failure: Recent advances and future perspectives ☆

Available online 31 March 2021
Yuling Luan | Xiaoni Kong | Yu Feng

Acute liver failure (ALF) is a life-threatening disease characterized by the rapid development of hepatocyte death and a systemic inflammatory response, which leads to high mortality. Despite the prevention...

Liver-specific deletion of mechanistic target of rapamycin does not protect against acetaminophen-induced liver injury in mice

Available online 19 March 2021
Hua Sun | Hong-Min Ni | Jennifer M. McCracken | Jephte Y. Akakpo | Sam Fulte | Tara McKeen | Hartmut Jaeschke | Hua Wang | Wen-Xing Ding

Acetaminophen (APAP) overdose can cause liver injury and liver failure, which is one of the most common causes of drug-induced liver injury in the United States. Pharmacological activation of autophagy...

Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets

Available online 9 March 2021
Syeda Maliha | Grace L. Guo

The farnesoid X receptor (FXR) is a nuclear receptor and transcriptional regulator activated by bile acids or synthetic FXR agonists. FXR is expressed highly in the liver and intestine where modulation...

Clinical perspectives of isoniazid-induced liver injury

Available online 11 February 2021
Saifei Lei | Ruizhi Gu | Xiaochao Ma

Isoniazid (INH) is a synthetic anti-mycobacterial agent used to treat active or latent tuberculosis (TB). INH has been in clinical use for nearly 70 years and remains broadly utilized at the front line...

Hsa-miR-637 inhibits human hepatocyte proliferation by targeting Med1-interacting proteins

Available online 23 January 2021
Jing Liu | Jianyun Zhu | Xiaohong Zhang | Yuzhi Jia | Xuejun Lee | Zhiliang Gao

Recent studies have shown that mediator complex subunit 1 (Med1) can significantly affect hepatocyte proliferation and differentiation. Acting as a tumor suppressor, microRNA-637 (hsa-miR-637) can inhibit...

Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma

December 2020
Tsung-Chieh Shih | Lijun Wang | Hsiao-Chi Wang | Yu-Jui Yvonne Wan

Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot...

Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies

December 2020
Steven D. Colquhoun

Hepatocellular carcinoma (HCC) accounts for the vast majority of primary hepatic malignancies. The overall incidence of this disease has always been significant, but in recent years it has continued...

Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years

December 2020
Kyohei Tsuchiya | Takamasa Ohki | Koki Sato | Mayuko Kondo | Nobuo Toda | Kazumi Tagawa

Although radiofrequency ablation (RFA) is a minimally invasive treatment for early-stage hepatocellular carcinoma (HCC), it remains unclear whether RFA achieves favorable outcomes in patients aged ≥80...

Hepatocellular carcinoma diagnosis and treatment: An overview

December 2020
Steven D. Colquhoun | Yu-Jui Yvonne Wan

Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma

December 2020
Tahereh Setayesh | Steven D. Colquhoun | Yu-Jui Yvonne Wan

Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans. Abnormal expression of Gals is associated with the development, progression, and metastasis of different...

Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization

December 2020
Xia Qian | Wei Zhang | Alireza Shams | Kahee Mohammed | Alex S. Befeler | Ningling Kang | Jinping Lai

The transcriptional co-activator Yes-associated protein-1 (YAP1) has been implicated as an oncogene and is overexpressed in different kinds of human cancers, especially hepatocellular carcinoma (HCC)....

Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome

December 2020
Farzam Vaziri | Steven D. Colquhoun | Yu-Jui Yvonne Wan

The incidence of hepatocellular carcinoma (HCC) has been increasing for decades. This disease has now risen to become the sixth most common malignancy overall, while ranking as the third most frequent...

Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma

December 2020
Takamasa Ohki | Koki Sato | Mayuko Kondo | Eriko Goto | Takahisa Sato | Yuji Kondo | Masatoshi Akamatsu | Shinpei Sato | Hideo Yoshida | Yukihiro Koike | Shuntaro Obi

Lenvatinib (LEN) is a newly developed tyrosine kinase inhibitor, and is approved as a first-line treatment for advanced hepatocellular carcinoma (HCC) in Japan. This retrospective multi-center study...

Golgi protein 73, hepatocellular carcinoma and other types of cancers

December 2020
Yanan Wang | Yu-Jui Yvonne Wan

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a low survival rate. The identification of mechanisms underlying the development of HCC helps uncover cellular and molecular...

Metformin alleviates cholestasis-associated nephropathy through regulating oxidative stress and mitochondrial function

Available online 10 December 2020
Mohammad Mehdi Ommati | Hamidreza Mohammadi | Khadijeh Mousavi | Negar Azarpira | Omid Farshad | Reyhaneh Dehghani | Asma Najibi | Sedigheh Kamran | Hossein Niknahad | Reza Heidari

Cholestasis-associated renal injury or cholemic nephropathy (CN) is a serious clinical problem. Previous studies mentioned that oxidative stress and mitochondrial impairment play a role in CN. There...

Mitigation of cholestasis-associated hepatic and renal injury by edaravone treatment: Evaluation of its effects on oxidative stress and mitochondrial function

Available online 10 November 2020
Mohammad Mehdi Ommati | Hanie Attari | Asma Siavashpour | Marzieh Shafaghat | Negar Azarpira | Hasti Ghaffari | Leila Moezi | Reza Heidari

The liver is the primary organ affected by cholestasis, and complications such as renal injury, renal failure, and the need for renal transplantation are associated with cholestatic liver disease. There...

Real-world effectiveness and safety of OBT/PTV/r and dasabuvir for patients with chronic HCV genotype 1b infection in China: A multicenter prospective observational study

September 2020
Yusheng Jie | Chaoshuang Lin | Jing Yuan | Zhixin Zhao | Yujuan Guan | Yuanping Zhou | Xiaohui Zhou | Bihui Zhong | Yinong Ye | Lihua Zhang | Ling Tao | Jianping Li | Xiaohong Zhang | Yutian Chong

Real-world data on the effectiveness and safety of treatment with the direct-acting antiviral agent-based regimen are limited on the Chinese mainland. The aim of this study was to conduct a multicenter,...

B lymphocyte-mediated humoral immunity in the pathogenesis of chronic hepatitis B infection

September 2020
Jing Pan | Tiantian Yao | Hao Cheng | Yan Zhu | Yan Wang

During hepatitis B virus (HBV) infection, the host immune response, including the presence of functional HBV-specific T cells and HBV-specific antibody-producing B cells, ultimately determines the HBV...

Pre-treatment twice with liposomal clodronate protects against acetaminophen hepatotoxicity through a pre-conditioning effect

September 2020
Melissa M. Clemens | Joel H. Vazquez | Stefanie Kennon-McGill | Sandra S. McCullough | Laura P. James | Mitchell R. McGill

Acetaminophen (APAP) overdose is a major cause of acute liver injury, but the role of macrophages in the propagation of the hepatotoxicity is controversial. Early research revealed that macrophage inhibitors...

Platelets: A review of their function and effects in liver diseases

September 2020
Haoqi Chen | Xiaolong Chen | Genshu Wang

Platelets are small fragments of the cytoplasm and are detached from the cytoplasm of mature megakaryocytes. They play an important role in the function of blood coagulation in humans. Recent studies...

Multidisciplinary, three-dimensional and individualized comprehensive treatment for severe/critical COVID-19

September 2020

Severe/critical cases account for 18–20% of all novel coronavirus disease 2019 (COVID-19) patients, but their mortality rate can be up to 61.5%. Furthermore, all deceased patients were severe/critical...

The progress of epigenetics in the development and progression of non-alcoholic fatty liver disease

September 2020
Fen Xu | Wanrong Guo

Non-alcoholic fatty liver disease (NAFLD) has become a global epidemic nowadays. Although the pathogenesis of NAFLD remains to be uncovered, it is highly correlated with the changing of environment...

Adoptive transfer of Pfkfb3-disrupted hematopoietic cells to wild-type mice exacerbates diet-induced hepatic steatosis and inflammation

September 2020
Xin Guo | Bilian Zhu | Hang Xu | Honggui Li | Boxiong Jiang | Yina Wang | Benrong Zheng | Shannon Glaser | Gianfranco Alpini | Chaodong Wu

Hepatic steatosis and inflammation are key characteristics of non-alcoholic fatty liver disease (NAFLD). However, whether and how hepatic steatosis and liver inflammation are differentially regulated...

Liver-specific microRNA-185 knockout promotes cholesterol dysregulation in mice

Available online 10 September 2020
Cheng Chen | David Matye | Yifeng Wang | Tiangang Li

The liver plays a key role in regulating whole body cholesterol homeostasis. Hepatic cholesterol accumulation causes liver injury in fatty liver disease and hypercholesterolemia increases the risk of...

Nuclear receptors and non-alcoholic fatty liver disease: An update

June 2020
Xiao Yang | Frank J. Gonzalez | Min Huang | Huichang Bi

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease in adults and children worldwide. The symptoms of NAFLD range from simple steatosis and non-alcoholic...

Intestinal barrier function and metabolic/liver diseases

June 2020
Siddhartha S. Ghosh | Jing Wang | Paul J. Yannie | Shobha Ghosh

Dietary, environmental or genetic changes contribute to the development of several metabolic and neurological diseases. Extensive research efforts have been directed towards examining how these factors...

The metabolite, alpha-ketoglutarate inhibits non-alcoholic fatty liver disease progression by targeting lipid metabolism

June 2020
Katsuya Nagaoka | Joud Mulla | Kevin Cao | Zhixiang Cheng | Dan Liu | William Mueller | Amalia Bay | Grace Hildebrand | Shaolei Lu | Chiung-Kuei Huang

Non-alcoholic liver disease is of increased concern and contributing to economic burdens not only in developing countries but in developed countries as well. Identifying the biomarker of early diagnosis...

Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis

June 2020
John Y.L. Chiang | Jessica M. Ferrell

Cholesterol 7 alpha-hydroxylase (CYP7A1, EC1.14) is the first and rate-limiting enzyme in the classic bile acid synthesis pathway. Much progress has been made in understanding the transcriptional regulation...

Efficacy and safety of direct-acting antiviral agent regimens in a real-world cohort of adult Chinese patients with chronic hepatitis C virus infection

June 2020
Jinyuan Wei | Yongyu Mei | Jianping Li | Jing Yuan | Xiaohua Yang | Zhen Xu | Guoli Lin | Juan Zhang | Zhixin Zhao | Xiaohong Zhang

To investigate the safety and efficacy of direct-acting antiviral (DAA) regimens in a cohort of Chinese patients with chronic hepatitis C virus (HCV) infection....

MiR-22 as a metabolic silencer and liver tumor suppressor

June 2020
Lijun Wang | Yu-Shiuan Wang | Eko Mugiyanto | Wei-Chiao Chang | Yu-Jui Yvonne Wan

With obesity rate consistently increasing, a strong relationship between obesity and fatty liver disease has been discovered. More than 90% of bariatric surgery patients also have non-alcoholic fatty...

Dysregulation of glutathione synthesis in liver disease

June 2020
Shelly C. Lu

Glutathione (GSH), a tripeptide that is present in all mammalian tissues, is especially highly concentrated in the liver. GSH synthesis occurs via two adenosine triphosphate (ATP)-requiring enzymatic...

Functional cure of chronic hepatitis B: Efforts and prospects

March 2020
Zhishuo Mo | Weiqiang Gan | Qiyi Zhao | Yalin Yin | Zhiliang Gao

The expression status of ZIC2 is an independent prognostic marker of hepatocellular carcinoma

March 2020
Qinglei Kong | Wenchao Li | Pan Hu | Hua Zeng | Yuhang Pan | Taicheng Zhou | Kunpeng Hu

Zinc finger protein of cerebellum 2 (ZIC2) is a transcriptional activator or repressor that is important for the organogenesis of the central nervous system. Previous studies have reported that ZIC2...

The alteration of immune cells in the pathogenesis of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

March 2020
Dechun Feng

The prevalence of non-alcoholic fatty liver disease (NAFLD) increases rapidly in recent decades. NAFLD has become a major public health problem in China and the whole world, and it is considered as...

Lipid and energy metabolism in Wilson disease

March 2020
Tagreed A. Mazi | Noreene M. Shibata | Valentina Medici

Copper accumulation and deficiency are reciprocally connected to lipid metabolism. In Wilson disease (WD), which is caused by a genetic loss of function of the copper-transporting P-type ATPase beta,...

Functional roles of CCL5/RANTES in liver disease

March 2020
Lili Chen | Qianfei Zhang | Chang Yu | Fang Wang | Xiaoni Kong

Inflammation, which is mediated by leukocyte trafficking and activation, plays a prominent role in the pathogenesis of acute and chronic liver injury. Chemokines are critical mediators involved in the...

The roles of zinc finger proteins in non-alcoholic fatty liver disease

March 2020
Guoqiang Li | Xinran Ma | Lingyan Xu

Non-alcoholic fatty liver disease (NAFLD) is a common chronic disease characterized by excessive fat accumulation in hepatocytes in the absence of alcohol consumption. Modern trends towards excessive...

Share this page: